ロード中...
Simeprevir for the treatment of hepatitis C virus infection
Simeprevir (TMC435, Olysio™), a second-generation hepatitis C virus (HCV) protease inhibitor, has been recently approved for the treatment of genotype 1 chronic hepatitis C in combination with pegylated interferon and ribavirin. This molecule has very different characteristics from first-generation...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4157399/ https://ncbi.nlm.nih.gov/pubmed/25206310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S52715 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|